NCT01184820View on ClinicalTrials.gov

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 13, 2010

Primary Completion Date

October 10, 2011

Study Completion Date

October 10, 2011

Conditions
Hemophilia A
Interventions
BIOLOGICAL

BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.

BIOLOGICAL

BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))

Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.

Trial Locations (4)

13210

Syracuse

55455

Minneapolis

95616

Davis

02115-6195

Boston

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY